Rapamycin increases catalase and superoxide dismutase and reduces NLRP3 gene expression, thereby suppressing pentylenetetrazole-induced anxiety and depression-like manifestations (Aghaie et al., 2021). This evidence concerns the gene NLRP3 and major depressive disorder.